Form 4: Verona Pharma General Counsel Exercises Options and Sells Shares Under Pre-Arranged Plan

Verona Pharma plc's General Counsel, Andrew Fisher, executed a pre-planned transaction on June 16, 2025, exercising options to acquire 80,000 ordinary shares and subsequently selling an equal number of shares.

Summary

• Andrew Fisher, General Counsel of Verona Pharma plc (VRNA), engaged in a transaction on June 16, 2025.
• He acquired 80,000 Ordinary Shares by exercising share options at an exercise price of $2.0113 per share.
• Concurrently, he sold 80,000 Ordinary Shares at a weighted average price of $11.525 per share.
• The sale was conducted pursuant to a Rule 10b5-1 plan, which was established on January 15, 2025.
• The sale price ranged from $11.3994 to $11.7825 per Ordinary Share, or $91.195 to $94.26 per American Depositary Share (ADS).
• Following these transactions, Mr. Fisher beneficially owns 359,999 Ordinary Shares directly.
• He also holds 2,240,000 Share Options, with 25% having vested on March 4, 2025, and the remainder vesting in 36 equal monthly installments.
• Each American Depositary Share (ADS) represents eight (8) Ordinary Shares of Verona Pharma plc.

Sentiment

Score: 5

Explanation: Neutral. While an insider sale can be seen negatively, the fact it was done under a Rule 10b5-1 plan mitigates concerns that it's based on new, negative information. It's a routine liquidity event for an executive.

Positives

• Management exercising options indicates confidence in the company's long-term value, as they are acquiring shares.
• The sale was executed at a significantly higher price ($11.525) than the exercise price ($2.0113), indicating a substantial gain for the insider.
• The transaction was conducted under a pre-arranged Rule 10b5-1 plan, which suggests the sale was not based on new, non-public information.

Negatives

• The sale of 80,000 Ordinary Shares by a General Counsel could be perceived as a negative signal by some investors, as it reduces insider ownership.

Future Outlook

NA

Industry Context

NA

Corporate Governance

Stakeholder Impact

• Shareholders: The sale by a General Counsel, even under a 10b5-1 plan, might be viewed with slight caution as it reduces insider ownership, though the pre-planned nature lessens the negative signal. The significant profit realized by the insider highlights the stock's appreciation.

Next Steps

• Continued vesting of remaining share options in 36 equal monthly installments.

Key Dates

Recommendation

Keywords

Verona Pharma, VRNA, SEC Form 4, Insider Trading, Share Options, Stock Sale, Rule 10b5-1, Andrew Fisher, General Counsel, Ordinary Shares, ADS